See more : Black Tusk Resources Inc. (BTKRF) Income Statement Analysis – Financial Results
Complete financial analysis of ImmuCell Corporation (ICCC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmuCell Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Consec Corporation (9895.T) Income Statement Analysis – Financial Results
- Ozu Corporation (7487.T) Income Statement Analysis – Financial Results
- Decibel Cannabis Company Inc. (DB.V) Income Statement Analysis – Financial Results
- China Art Financial Holdings Limited (1572.HK) Income Statement Analysis – Financial Results
- Hanfeng Evergreen Inc. (HFGVF) Income Statement Analysis – Financial Results
ImmuCell Corporation (ICCC)
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.47M | 18.57M | 19.24M | 15.34M | 13.72M | 10.99M | 10.43M | 9.54M | 10.23M | 7.60M | 6.01M | 5.39M | 5.11M | 4.39M | 4.51M | 4.63M | 6.07M | 4.80M | 4.98M | 3.70M | 3.36M | 6.18M | 6.68M | 5.64M | 4.91M | 4.50M | 4.60M | 4.40M | 4.90M | 4.40M | 3.90M | 3.10M | 2.20M | 3.00M | 2.80M |
| Cost of Revenue | 13.08M | 10.92M | 10.59M | 8.48M | 6.98M | 5.79M | 5.21M | 4.12M | 3.98M | 3.15M | 2.95M | 2.34M | 2.30M | 2.08M | 2.11M | 2.56M | 2.27M | 1.88M | 1.63M | 1.45M | 1.35M | 2.80M | 3.22M | 2.67M | 2.05M | 1.90M | 1.70M | 1.80M | 1.80M | 1.80M | 1.70M | 1.40M | 1.30M | 1.10M | 1.50M |
| Gross Profit | 4.40M | 7.65M | 8.66M | 6.86M | 6.74M | 5.19M | 5.22M | 5.42M | 6.25M | 4.45M | 3.06M | 3.05M | 2.81M | 2.30M | 2.40M | 2.07M | 3.80M | 2.92M | 3.35M | 2.25M | 2.01M | 3.39M | 3.46M | 2.97M | 2.86M | 2.60M | 2.90M | 2.60M | 3.10M | 2.60M | 2.20M | 1.70M | 900.00K | 1.90M | 1.30M |
| Gross Profit Ratio | 25.16% | 41.19% | 44.98% | 44.73% | 49.11% | 47.28% | 50.05% | 56.80% | 61.11% | 58.56% | 50.95% | 56.67% | 55.05% | 52.49% | 53.25% | 44.77% | 62.62% | 60.79% | 67.21% | 60.80% | 59.87% | 54.74% | 51.85% | 52.66% | 58.21% | 57.78% | 63.04% | 59.09% | 63.27% | 59.09% | 56.41% | 54.84% | 40.91% | 63.33% | 46.43% |
| Research & Development | 4.39M | 4.49M | 4.17M | 4.35M | 3.69M | 3.52M | 2.05M | 1.24M | 1.24M | 2.18M | 1.15M | 917.60K | 1.72M | 1.49M | 1.64M | 1.75M | 1.58M | 965.93K | 1.27M | 1.09M | 1.35M | 1.05M | 849.00K | 922.35K | 812.89K | 1.00M | 1.10M | 1.30M | 1.50M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.13M | 2.26M | 1.73M | 1.72M | 1.69M | 1.74M | 1.52M | 1.45M | 1.29M | 1.16M | 939.19K | 918.44K | 856.61K | 849.06K | 872.53K | 926.29K | 1.35M | 1.18M | 1.14M | 1.03M | 1.09M | 1.80M | 1.94M | 1.50M | 1.33M | 1.50M | 1.40M | 1.30M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.09M | 5.45M | 4.23M | 3.89M | 4.01M | 3.82M | 3.42M | 1.83M | 1.61M | 1.32M | 986.77K | 973.22K | 869.87K | 650.89K | 410.74K | 569.71K | 0.00 | 401.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.22M | 5.45M | 4.23M | 3.89M | 4.01M | 3.82M | 3.42M | 3.29M | 2.89M | 2.48M | 1.93M | 1.89M | 1.73M | 1.50M | 1.28M | 1.50M | 1.35M | 1.18M | 1.14M | 1.03M | 1.09M | 1.80M | 1.94M | 1.50M | 1.33M | 1.50M | 1.40M | 1.30M | 1.40M | 1.30M | 2.20M | 1.90M | 2.20M | 2.30M | 2.10M |
| Other Expenses | 0.00 | -187.00K | -326.00K | 348.00K | -314.00K | -413.00K | -195.00K | -24.85K | 5.64K | -3.90K | 31.90K | 8.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 133.16K | 101.54K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Operating Expenses | 9.62M | 9.95M | 8.40M | 8.24M | 7.69M | 7.34M | 5.46M | 4.53M | 4.13M | 4.66M | 3.08M | 2.81M | 3.45M | 2.99M | 2.93M | 3.24M | 2.93M | 2.15M | 2.41M | 2.13M | 2.44M | 2.85M | 2.79M | 2.55M | 2.24M | 2.60M | 2.60M | 2.70M | 3.10M | 2.90M | 2.30M | 2.00M | 2.30M | 2.40M | 2.20M |
| Cost & Expenses | 23.22M | 20.87M | 18.99M | 16.72M | 14.68M | 13.13M | 10.67M | 8.65M | 8.11M | 7.80M | 6.03M | 5.14M | 5.74M | 5.08M | 5.04M | 5.80M | 5.20M | 4.03M | 4.05M | 3.58M | 3.79M | 5.65M | 6.01M | 5.22M | 4.29M | 4.50M | 4.30M | 4.50M | 4.90M | 4.70M | 4.00M | 3.40M | 3.60M | 3.50M | 3.70M |
| Interest Income | 0.00 | 153.10K | 18.81K | 27.44K | 118.28K | 14.30K | 16.91K | 54.66K | 19.17K | 15.55K | 12.49K | 17.20K | 15.00K | 26.00K | 96.29K | 204.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 340.88K | 314.36K | 412.69K | 431.79K | 427.78K | 218.57K | 161.70K | 80.24K | 57.83K | 66.69K | 75.27K | 81.00K | 22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.72M | 2.49M | 2.47M | 2.36M | 2.27M | 1.52M | 904.44K | 802.38K | 529.26K | 448.92K | 417.20K | 402.52K | 418.37K | 419.51K | 424.44K | 399.10K | 788.90K | 278.52K | 643.62K | 278.52K | 256.27K | 236.77K | 177.00K | 133.16K | 101.54K | 100.00K | 100.00K | 100.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| EBITDA | -2.50M | 349.99K | 2.72M | 1.65M | 1.43M | 88.44K | 684.53K | 1.72M | 2.65M | 251.30K | 692.04K | 672.82K | -192.31K | -241.90K | -4.07K | -768.49K | 1.66M | 1.05M | 1.58M | 399.29K | -172.76K | 769.91K | 847.61K | 546.53K | 716.51K | 100.00K | 400.00K | 0.00 | 200.00K | -100.00K | 0.00 | -200.00K | -1.30M | -400.00K | -800.00K |
| EBITDA Ratio | -14.33% | -12.38% | 1.34% | -8.99% | -6.95% | -25.91% | -2.33% | 18.05% | 26.13% | 3.31% | 7.31% | 12.43% | -3.90% | -5.58% | -2.32% | -16.64% | 27.45% | 21.95% | 31.63% | 10.80% | -37.89% | -2.68% | 8.48% | 9.70% | 16.57% | 2.22% | 8.70% | 2.27% | 4.08% | -4.55% | 0.00% | -6.45% | -59.09% | -13.33% | -28.57% |
| Operating Income | -5.75M | -2.30M | -2.20M | -1.38M | -954.00K | -1.45M | -243.00K | 890.20K | 2.12M | -206.40K | -19.55K | 245.00K | -632.73K | -690.28K | -527.03K | -1.17M | 872.10K | 770.68K | 938.03K | 120.77K | -429.03K | 533.14K | 671.00K | 413.37K | 614.97K | 0.00 | 300.00K | -100.00K | 0.00 | -300.00K | -100.00K | -300.00K | -1.40M | -500.00K | -900.00K |
| Operating Income Ratio | -32.90% | -12.38% | -11.45% | -8.99% | -6.95% | -13.17% | -2.33% | 9.33% | 20.75% | -2.72% | -0.33% | 4.55% | -12.38% | -15.74% | -11.69% | -25.20% | 14.37% | 16.05% | 18.82% | 3.27% | -12.78% | 8.62% | 10.05% | 7.33% | 12.53% | 0.00% | 6.52% | -2.27% | 0.00% | -6.82% | -2.56% | -9.68% | -63.64% | -16.67% | -32.14% |
| Total Other Income/Expenses | -21.89K | -187.19K | -326.51K | 348.10K | -313.51K | -413.48K | -195.64K | -131.88K | -58.77K | -49.05K | 224.81K | -52.85K | -63.96K | 6.87K | 98.53K | 206.94K | 271.54K | 263.37K | 133.05K | 56.42K | 1.15M | 948.24K | 26.04K | 62.51K | -97.13K | 0.00 | 0.00 | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -5.77M | -2.49M | -69.00K | -1.03M | -1.27M | -1.86M | -438.00K | 758.32K | 2.06M | -255.45K | 205.26K | 192.15K | -696.68K | -683.41K | -428.50K | -960.65K | 1.14M | 1.03M | 1.07M | 177.19K | 716.38K | 1.48M | 697.00K | 475.89K | 517.84K | 0.00 | 0.00 | 0.00 | 0.00 | -200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -33.02% | -13.39% | -0.36% | -6.73% | -9.24% | -16.93% | -4.20% | 7.95% | 20.17% | -3.36% | 3.42% | 3.57% | -13.63% | -15.58% | -9.50% | -20.73% | 18.84% | 21.54% | 21.49% | 4.79% | 21.34% | 23.95% | 10.44% | 8.44% | 10.55% | 0.00% | 0.00% | 0.00% | 0.00% | -4.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.63K | 8.00K | 9.00K | -10.00K | 28.00K | 462.00K | -270.00K | 249.87K | 850.31K | -88.29K | 87.87K | 102.64K | -287.17K | -298.73K | -212.01K | -492.10K | 481.51K | 386.91K | 363.31K | 33.67K | 305.16K | 595.15K | 277.00K | -1.75M | 64.13K | 100.00K | 0.00 | 100.00K | 0.00 | -200.00K | 0.00 | -100.00K | 0.00 | 100.00K | 100.00K |
| Net Income | -5.77M | -2.49M | -78.00K | -1.02M | -1.30M | -2.32M | -168.00K | 508.45K | 1.21M | -167.16K | 117.40K | 89.51K | -409.51K | -384.68K | -216.49K | -468.56K | 662.14K | 647.14K | 707.78K | 143.52K | 411.22K | 886.24K | 420.00K | 2.22M | 550.84K | -100.00K | 300.00K | -100.00K | 0.00 | -100.00K | 0.00 | -200.00K | -1.40M | -600.00K | -1.00M |
| Net Income Ratio | -33.05% | -13.43% | -0.41% | -6.66% | -9.44% | -21.14% | -1.61% | 5.33% | 11.86% | -2.20% | 1.95% | 1.66% | -8.01% | -8.77% | -4.80% | -10.11% | 10.91% | 13.48% | 14.20% | 3.88% | 12.25% | 14.33% | 6.29% | 39.43% | 11.22% | -2.22% | 6.52% | -2.27% | 0.00% | -2.27% | 0.00% | -6.45% | -63.64% | -20.00% | -35.71% |
| EPS | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.40 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 | -0.16 | 0.23 | 0.22 | 0.25 | 0.05 | 0.15 | 0.32 | 0.15 | 0.84 | 0.23 | -0.04 | 0.11 | -0.04 | 0.01 | -0.06 | -0.01 | -0.11 | -0.69 | -0.28 | -0.50 |
| EPS Diluted | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.38 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 | -0.16 | 0.22 | 0.21 | 0.24 | 0.05 | 0.15 | 0.32 | 0.15 | 0.79 | 0.22 | -0.04 | 0.10 | -0.04 | 0.01 | -0.06 | -0.01 | -0.11 | -0.69 | -0.28 | -0.50 |
| Weighted Avg Shares Out | 7.70M | 7.75M | 7.59M | 7.21M | 6.82M | 5.49M | 4.95M | 4.23M | 3.04M | 3.03M | 3.02M | 3.02M | 2.98M | 2.97M | 2.96M | 2.89M | 2.90M | 2.89M | 2.82M | 2.76M | 2.74M | 2.77M | 2.80M | 2.63M | 2.43M | 2.43M | 2.73M | 2.73M | 2.29M | 1.67M | 2.64M | 1.82M | 2.03M | 2.14M | 1.99M |
| Weighted Avg Shares Out (Dil) | 7.75M | 7.75M | 7.59M | 7.21M | 6.82M | 5.49M | 4.95M | 4.34M | 3.17M | 3.03M | 3.09M | 3.11M | 2.98M | 2.97M | 2.96M | 2.89M | 3.03M | 3.05M | 3.00M | 2.97M | 2.82M | 2.77M | 2.80M | 2.82M | 2.52M | 2.43M | 3.00M | 2.73M | 2.50M | 1.67M | 2.64M | 1.82M | 2.03M | 2.14M | 1.99M |
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.
ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Participants George Melas - MKH Management Operator Good morning and...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024
Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef...
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef...
Source: https://incomestatements.info
Category: Stock Reports